The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of Matinas Biopharma Holdings Inc (AMEX: MTNB) closed at $0.70 in the last session, up 17.08% from day before closing price of $0.60. In other words, the price has increased by $17.08 from its previous closing price. On the day, 13.03 million shares were traded. MTNB stock price reached its highest trading level at $0.99 during the session, while it also had its lowest trading level at $0.5726.
Ratios:
We take a closer look at MTNB’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 5.53 and its Current Ratio is at 5.53. In the meantime, Its Debt-to-Equity ratio is 0.19 whereas as Long-Term Debt/Eq ratio is at 0.15.
On January 27, 2020, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $3.Piper Sandler initiated its Overweight rating on January 27, 2020, with a $3 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MTNB now has a Market Capitalization of 3560893 and an Enterprise Value of -7889644.
Stock Price History:
The Beta on a monthly basis for MTNB is 1.56, which has changed by -0.94304764 over the last 52 weeks, in comparison to a change of 0.23147523 over the same period for the S&P500. Over the past 52 weeks, MTNB has reached a high of $21.50, while it has fallen to a 52-week low of $0.48. The 50-Day Moving Average of the stock is 14.99%, while the 200-Day Moving Average is calculated to be -87.49%.
Shares Statistics:
According to the various share statistics, MTNB traded on average about 292.89K shares per day over the past 3-months and 455650 shares per day over the past 10 days. A total of 5.09M shares are outstanding, with a floating share count of 4.70M. Insiders hold about 7.66% of the company’s shares, while institutions hold 10.94% stake in the company. Shares short for MTNB as of 1730332800 were 32365 with a Short Ratio of 0.38, compared to 1727654400 on 62660. Therefore, it implies a Short% of Shares Outstanding of 32365 and a Short% of Float of 0.66000004.
Earnings Estimates
The market rating of Matinas Biopharma Holdings Inc (MTNB) is currently shaped by the ongoing analysis conducted by 1.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$4.06 and -$4.06 for the fiscal current year, implying an average EPS of -$4.06. EPS for the following year is -$3.0, with 2.0 analysts recommending between -$1.5 and -$4.5.
